Rachel Humphrey - Net Worth and Insider Trading

Rachel Humphrey Net Worth

The estimated net worth of Rachel Humphrey is at least $49,584 dollars as of 2024-06-09. Rachel Humphrey is the Chief Medical Officer of CytomX Therapeutics Inc and owns about 30,234 shares of CytomX Therapeutics Inc (CTMX) stock worth over $49,584. Details can be seen in Rachel Humphrey's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Rachel Humphrey has not made any transactions after 2018-03-02 and currently still holds the listed stock(s).

Transaction Summary of Rachel Humphrey

To

Rachel Humphrey Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Rachel Humphrey owns 5 companies in total, including Black Diamond Therapeutics Inc (BDTX) , CytomX Therapeutics Inc (CTMX) , and Mirati Therapeutics Inc (MRTX) among others .

Click here to see the complete history of Rachel Humphrey’s form 4 insider trades.

Insider Ownership Summary of Rachel Humphrey

Ticker Comapny Transaction Date Type of Owner
BDTX Black Diamond Therapeutics Inc 2020-09-08 Chief Medical Officer
CTMX CytomX Therapeutics Inc 2018-03-02 Chief Medical Officer
MRTX Mirati Therapeutics Inc 2013-07-12 EVP and Chief Medical Officer
LIMIT LIMIT 2021-10-21 director
LIMIT LIMIT 2022-08-11 director

Rachel Humphrey Latest Holdings Summary

Rachel Humphrey currently owns a total of 1 stock. Rachel Humphrey owns 30,234 shares of CytomX Therapeutics Inc (CTMX) as of March 2, 2018, with a value of $49,584.

Latest Holdings of Rachel Humphrey

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CTMX CytomX Therapeutics Inc 2018-03-02 30,234 1.64 49,584

Holding Weightings of Rachel Humphrey


Rachel Humphrey Form 4 Trading Tracker

According to the SEC Form 4 filings, Rachel Humphrey has made a total of 0 transactions in CytomX Therapeutics Inc (CTMX) over the past 5 years. The most-recent trade in CytomX Therapeutics Inc is the sale of 16,160 shares on March 2, 2018, which brought Rachel Humphrey around $484,800.

Insider Trading History of Rachel Humphrey

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Rachel Humphrey Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Rachel Humphrey Ownership Network

Ownership Network List of Rachel Humphrey

No Data

Ownership Network Relation of Rachel Humphrey

Insider Network Chart

Rachel Humphrey Owned Company Details

What does Black Diamond Therapeutics Inc do?

Who are the key executives at Black Diamond Therapeutics Inc?

Rachel Humphrey is the Chief Medical Officer of Black Diamond Therapeutics Inc. Other key executives at Black Diamond Therapeutics Inc include 10 percent owner Biotech Growth N V , director & 10 percent owner Ali Behbahani , and director & See Remarks David M. Epstein .

Black Diamond Therapeutics Inc (BDTX) Insider Trades Summary

Over the past 18 months, Rachel Humphrey made no insider transaction in Black Diamond Therapeutics Inc (BDTX). Other recent insider transactions involving Black Diamond Therapeutics Inc (BDTX) include a net purchase of 3,140,000 shares made by Biotech Growth N V , a net purchase of 1,000,000 shares made by Ali Behbahani , and a net purchase of 935,850 shares made by Ra Capital Healthcare Fund Lp .

In summary, during the past 3 months, insiders sold 0 shares of Black Diamond Therapeutics Inc (BDTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,000 shares of Black Diamond Therapeutics Inc (BDTX) were sold and 5,132,213 shares were bought by its insiders, resulting in a net purchase of 5,107,213 shares.

Black Diamond Therapeutics Inc (BDTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Black Diamond Therapeutics Inc Insider Transactions

No Available Data

Rachel Humphrey Mailing Address

Above is the net worth, insider trading, and ownership report for Rachel Humphrey. You might contact Rachel Humphrey via mailing address: C/o Mirati Therapeutics Inc., 4660 La Jolla Village Drive, Suite 500, San Diego Ca 92121.

Discussions on Rachel Humphrey

No discussions yet.